181 related articles for article (PubMed ID: 21449604)
21. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Witzel I; Loibl S; von Minckwitz G; Eidtmann H; Fehm T; Khandan F; Schmatloch S; Hauschild M; Bischoff J; Fasching PA; Mau C; Schem C; Rack B; Meinhold-Heerlein I; Liedtke C; Karn T; Huober J; Zu Eulenburg C; Issa-Nummer Y; Untch M; Müller V
Br J Cancer; 2012 Sep; 107(6):956-60. PubMed ID: 22892393
[TBL] [Abstract][Full Text] [Related]
22. Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer.
Shao X; Wang X; Xu X; Feng J; Han M; Zhang H; Chen ZH; Wang S; Zang YM; Huang P; Jin H; Wang X
Int J Clin Exp Pathol; 2014; 7(3):1108-13. PubMed ID: 24696727
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
[TBL] [Abstract][Full Text] [Related]
25. Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study.
Tryfonidis K; Marreaud S; Khaled H; De Valk B; Vermorken J; Welnicka-Jaskiewicz M; Aalders K; Bartlett JMS; Biganzoli L; Bogaerts J; Cameron D;
Breast Cancer Res Treat; 2017 Jun; 163(3):507-515. PubMed ID: 28324265
[TBL] [Abstract][Full Text] [Related]
26. Serum HER2 levels determined by two methods in patients with metastatic breast cancer.
Hayashi N; Nakamura S; Tokuda Y; Yagata H; Yoshida A; Ota H; Hortobagyi GN; Cristofanilli M; Ueno NT
Int J Clin Oncol; 2012 Feb; 17(1):55-62. PubMed ID: 21607830
[TBL] [Abstract][Full Text] [Related]
27. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
Ghedini GC; Ciravolo V; Tortoreto M; Giuffrè S; Bianchi F; Campiglio M; Mortarino M; Figini M; Coliva A; Carcangiu ML; Zambetti M; Piazza T; Ferrini S; Ménard S; Tagliabue E; Pupa SM
J Cell Physiol; 2010 Oct; 225(1):256-65. PubMed ID: 20506359
[TBL] [Abstract][Full Text] [Related]
28. HER2 targeted therapy in breast cancer...beyond Herceptin.
Pal SK; Pegram M
Rev Endocr Metab Disord; 2007 Sep; 8(3):269-77. PubMed ID: 17899385
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.
Nunes RA; Li X; Kang SP; Burstein H; Roberts L; Carney W; Blackwell K; Ryan P; Borges V; Iglehart JD; Friedman P; Harris LN
Int J Biol Markers; 2009; 24(1):1-10. PubMed ID: 19404916
[TBL] [Abstract][Full Text] [Related]
30. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
[TBL] [Abstract][Full Text] [Related]
31. HER2 testing to manage patients with breast cancer or other solid tumors.
Seidenfeld J; Samsom DJ; Rothenberg BM; Bonnell CJ; Ziegler KM; Aronson N
Evid Rep Technol Assess (Full Rep); 2008 Nov; (172):1-362. PubMed ID: 19408965
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract][Full Text] [Related]
33. A Multicolor Immunosensor for Sensitive Visual Detection of Breast Cancer Biomarker Based on Sensitive NADH-Ascorbic-Acid-Mediated Growth of Gold Nanobipyramids.
Wang Z; Chen Q; Zhong Y; Yu X; Wu Y; Fu F
Anal Chem; 2020 Jan; 92(1):1534-1540. PubMed ID: 31790576
[TBL] [Abstract][Full Text] [Related]
34. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
Disis ML; Wallace DR; Gooley TA; Dang Y; Slota M; Lu H; Coveler AL; Childs JS; Higgins DM; Fintak PA; dela Rosa C; Tietje K; Link J; Waisman J; Salazar LG
J Clin Oncol; 2009 Oct; 27(28):4685-92. PubMed ID: 19720923
[TBL] [Abstract][Full Text] [Related]
35. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
36. Impedimetric aptasensing of the breast cancer biomarker HER2 using a glassy carbon electrode modified with gold nanoparticles in a composite consisting of electrochemically reduced graphene oxide and single-walled carbon nanotubes.
Rostamabadi PF; Heydari-Bafrooei E
Mikrochim Acta; 2019 Jul; 186(8):495. PubMed ID: 31270702
[TBL] [Abstract][Full Text] [Related]
37. Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients.
Asgeirsson KS; Agrawal A; Allen C; Hitch A; Ellis IO; Chapman C; Cheung KL; Robertson JF
Breast Cancer Res; 2007; 9(6):R75. PubMed ID: 17976236
[TBL] [Abstract][Full Text] [Related]
38. Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro.
Hosseini Ghatar R; Soltantoyeh T; Bahadori M; Khoshnoodi J; Golsaz Shirazi F; Jeddi Tehrani M; Amiri MM; Shokri F
Iran J Immunol; 2017 Sep; 14(3):200-214. PubMed ID: 28919583
[TBL] [Abstract][Full Text] [Related]
39. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.
Vazquez-Martin A; Fernandez-Real JM; Oliveras-Ferraros C; Navarrete JM; Martin-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2009 Dec; 35(6):1369-76. PubMed ID: 19885560
[TBL] [Abstract][Full Text] [Related]
40. Prospect for anti-HER2 receptor therapy in breast cancer.
Brand FX; Ravanel N; Gauchez AS; Pasquier D; Payan R; Fagret D; Mousseau M
Anticancer Res; 2006; 26(1B):463-70. PubMed ID: 16739306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]